Clinical Trial Information
Expanded Access Protocol for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma- Category: Multiple Myeloma
- Status: Active
- Starts: Jan 30, 2023
- Trial Number: GSK2857916
Principal Investigator: Furhan Yunus, M.D.
Research Nurse: Wendy Blount, RN, MSN
Description of Trial:
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody.
For more information about this clinical trial from ClinicalTrials.gov, please click here.